Drug intelligence / Profile preview

PNC-004

Development stage: Preclinical
Lead developer: ProEncia Biotechnology
Modality: Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
Administration: Topical

Overview

PNC-004 is a topical over-the-counter (OTC) prophylactic product being developed by ProEncia Biotechnology for the prevention of periodontal disease. It is specifically designed for use by healthy individuals to maintain oral health and prevent the onset of gum disease. As part of ProEncia's pipeline of targeted oral therapeutics, PNC-004 represents an early-intervention approach intended to prevent the progression of periodontal conditions before clinical symptoms such as gingivitis or periodontitis manifest. The product is formulated for topical application to the oral cavity.

Beyond the preview

Go deeper on PNC-004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PNC-004.

Explore the full profile